The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations , with sales up 15.7% year on year to $2.91 billion. The company ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...

Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares. The firm is ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $459 from $450 and keeps an Equal ...

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

Jonathan Biller, Executive Vice President and Chief Legal Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), recently executed a significant stock sale. According to a recent SEC filing, Biller ...

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

Vertex Pharmaceuticals posted a double-digit increase in its quarterly revenue thanks to strong sales for its cystic-fibrosis treatment. The biotechnology company on Monday reported a profit of $ ...

Vertex Pharmaceuticals Incorporated VRTX will release its fourth-quarter financial results, after the closing bell, on Monday, Feb. 10, 2025. Analysts expect the Boston, Massachusetts-based ...